304360 — S Biomedics Co Balance Sheet
0.000.00%
- KR₩446bn
- KR₩455bn
- KR₩13bn
Annual balance sheet for S Biomedics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | Annual Audited Accounts |
Standards: | — | — | — | — | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 15,676 | 12,448 | 12,839 | 7,073 | 10,591 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 830 | 823 | 469 | 1,540 | 2,228 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 17,433 | 14,322 | 14,342 | 11,201 | 15,700 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4,489 | 3,357 | 3,051 | 2,765 | 4,962 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 22,283 | 18,065 | 17,796 | 24,358 | 31,947 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5,547 | 6,763 | 4,175 | 11,831 | 7,731 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 9,284 | 12,249 | 15,285 | 28,136 | 25,015 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 12,999 | 5,816 | 2,510 | -3,779 | 6,932 |
Total Liabilities & Shareholders' Equity | 22,283 | 18,065 | 17,796 | 24,358 | 31,947 |
Total Common Shares Outstanding |